SomaLogic wins shareholder approval for Standard BioTools deal
[ad_1]
©Reuters. BOULDER, Colo. – SomaLogic Corporation (NASDAQ: SLGC), a proteomics technology company, has received shareholder approval for a transaction with Standard BioTools Inc. (NASDAQ: LAB). The approval, based on a preliminary vote at a special meeting on Thursday, marks an important step in a merger that will create a diverse leader in the tools space. life sciences.
The SomaLogic Board of Directors expresses its gratitude to shareholders for their support, which they believe will enable the SomaLogic platform to realize significant value and provide a path to accelerated profitability. The merger, expected to close today, is seen as a strategic move to strengthen both companies’ positions in the market by leveraging their combined technologies and expertise to advance human health research.
Final voting results from the special meeting will be submitted to the SEC soon, as required by regulations.
Known for its protein measurement and analysis capabilities, SomaLogic supports a wide range of customers in the pharmaceutical industry as well as academic and contract research organizations.
The information in this article is based on press release statements.
This article was created and translated with the help of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.
